Treatment
S-1 clinical trials
We’re tracking 796 recruiting studies that include S-1, each written for real people, not researchers, below.
Recruiting studies
- NCT07708727RecruitingPhase 2/Phase 3
Injectable HIV treatment vs daily pill for new patients
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
Ft. Pierce, FloridaAges 18 years+ - NCT07595367RecruitingPhase 2
BBD-1 immune therapy for IgA vasculitis
This trial tests a new drug called BBD-1 that may help treat IgA vasculitis, a condition where your immune system attacks small blood vessels, causing a purple rash and organ damage. The study measures how well BBD-1 reduces symptoms and side effects.
Baltimore, MarylandAges Any age - NCT07227207RecruitingPhase 1/Phase 2
Study of TSRA-196 for adults with Alpha-1 Antitrypsin Deficiency
This trial tests a new medicine called TSRA-196 for people with Alpha-1 Antitrypsin Deficiency who have the PiZZ genetic type. The study looks at whether TSRA-196 can help with lung or liver problems related to this condition.
Boston, MassachusettsAges 18–70 - NCT07645287RecruitingPhase 2
New HIV Combination Therapy for People on Biktarvy
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
Beverly Hills, CaliforniaAges 18 years+ - NCT06988592Recruiting
Chemo plus immunotherapy for advanced bile duct cancer
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 inhibitor) as the first treatment for advanced bile duct or gallbladder cancer. It aims to see if this combination works better and to understand how the immune system responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06789679RecruitingPhase 2
Adding S-1 to standard chemo for advanced pancreatic cancer
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
Beijing, Chaoyang DistrictAges 18 years+ - NCT06462053RecruitingPhase 2
Short radiotherapy plus chemo and immunotherapy for early low rectal cancer
This study is testing whether a short course of radiation combined with chemotherapy and an immunotherapy drug works better than the standard longer radiation and chemotherapy for early-stage rectal cancer that is low in the rectum. The goal is to see if this shorter treatment can help patients avoid surgery or have a better outcome.
ShanghaiAges 18–75 - NCT06311942RecruitingPhase 4
Comparing triple vs. dual therapy after liver surgery for liver cancer
This trial tests whether adding a third drug to standard two-drug therapy after liver surgery helps prevent liver cancer from returning. It is for people who have a specific blood vessel pattern in their tumor, called VETC, seen on a special stain.
Wuhan, HubeiAges 18–75 - NCT06281405RecruitingPhase 2
CAPOX and immunotherapy with or without radiation for rectal cancer
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
ShanghaiAges 18–70 - NCT06203132RecruitingPhase 3
Doravirine vs Dolutegravir for first-time HIV treatment
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
Nova Iguaçu, Rio de JaneiroAges 18 years+ - NCT06311929RecruitingPhase 4
Personalized treatment after liver cancer surgery
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
Wuhan, HubeiAges 18–75 - NCT05403242RecruitingPhase 1/Phase 2
Study drug RC48-ADC plus S-1 for advanced HER2 stomach cancers
This Phase 1/2 study tests RC48-ADC (an antibody-drug treatment) together with S-1 (a chemotherapy medicine) in people with advanced stomach or esophagus/gastroesophageal junction cancer. It’s mainly for cancers with HER2 testing results of IHC 2+ and FISH-negative, and aims to find a safe dose and how well the treatment works as a first treatment option.
BeijingAges 18 years+ - NCT05143307Enrolling by invitationPhase 1
Follow-up study for adults who received EBT-101 for HIV
This study checks how adults are doing long-term after receiving an HIV treatment called EBT-101 in an earlier study. It helps researchers understand safety and longer-term effects over time.
San Francisco, CaliforniaAges 18 years+ - NCT05245474RecruitingPhase 2
Before-surgery chemoradiation plus PD-1 for locally advanced rectal cancer
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
Beijing, Beijing MunicipalityAges 18–75 - NCT04553081RecruitingPhase 4
Switching HIV treatment: 2-drug versus 3-drug plan
This trial compares two different HIV treatment plans: keeping you on a 2-drug regimen versus switching to a 3-drug regimen. It’s designed for people whose HIV is well controlled and looks at whether the switch is safe and effective.
GhentAges 18 years+ - NCT04144569RecruitingPhase 2
PD-1 plus pyrotinib for HER2-mutated lung cancer after chemo
This trial tests a combination treatment—PD-1 plus pyrotinib—in people with advanced lung cancer that has a specific HER2 “insertion” genetic change. It may help if your first standard chemotherapy did not work and you still have measurable tumors to track.
Changsha, HunanAges 18–75 - NCT06205602RecruitingPhase 2
HIV treatment with antibodies for a cure in Africa
This study tests if giving antibodies along with standard HIV medications can help control the virus without daily pills. It may lead to a functional cure for people living with HIV.
GaboroneAges 18–60 - NCT06475196Enrolling by invitation
Immunotherapy plus chemo before surgery for esophageal cancer
This trial tests a combination of immunotherapy (sintilimab) and chemotherapy given before surgery for esophageal cancer that can be surgically removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06751901RecruitingPhase 2
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized peptide vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation for people with advanced non-small cell lung cancer whose disease has gotten worse after at least two standard treatments. It aims to see if this triple therapy can help control the cancer.
Nanchang, JiangxiAges 18–70 - NCT07437911Recruiting
Can a Supplement Help with Nutrient Gaps for GLP-1 Users?
This study tests whether a daily supplement can help fill nutrient gaps and improve gut health for people who are already taking GLP-1 weight-loss medications (like Ozempic or Wegovy). Participants must be on a stable dose for at least 8 weeks and be generally healthy without other chronic conditions.
Santa Monica, CaliforniaAges 18–59 - NCT06928922RecruitingEarly Phase 1
Inhaled mRNA vaccine for advanced lung cancer and lung metastases
This trial tests an inhaled dry powder vaccine that uses mRNA to help your immune system target cancer cells in the lungs. It is for people with advanced lung cancer or solid tumors that have spread to the lungs, who have already tried standard treatments.
BeijingAges Up to 99 years - NCT06752044Recruiting
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Nanchang, JiangxiAges 18–70 - NCT07524452RecruitingPhase 3
Becotatug vedotin plus immunotherapy for head and neck cancer
This trial tests a new combination of two drugs—becotatug vedotin (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—given before surgery to treat advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve surgical outcomes for patients with specific cancer markers.
Zhuhai, GuangdongAges 18–75 - NCT06693440Recruiting
How PD-1 antibody therapy affects immune function in cancer
This trial is studying how PD-1 antibody therapy (a type of immunotherapy that helps your immune system fight cancer) affects the immune system in people with various cancers. It may be a good fit if you have a confirmed cancer diagnosis and have your medical records and immune test results available.
Zhengzhou, HenanAges 18 years+
Common questions
- Are there clinical trials studying S-1?
- Yes. Clin2 currently lists 796 recruiting studies that include S-1, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a S-1 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is S-1 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether S-1 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.